Article

AAO encourages CMS' coverage of intravitreal bevacizumab

In a letter to the Centers for Medicare and Medicaid Services(CMS), the American Academy of Ophthalmology (AAO) supportedreimbursement for treating age-related macular degeneration (AMD)with intravitreal injections of bevacizumab (Avastin, Genentech) inpatients who have not responded to therapy with the two Food andDrug Administration-approved and CMS-covered drug therapies--ocularphotodynamic therapy with verteporfin (Visudyne, Novartis) orintravitreal pegatanib (Macugen, Eyetech, Pfizer).

In a letter to the Centers for Medicare and Medicaid Services (CMS), the American Academy of Ophthalmology (AAO) supported reimbursement for treating age-related macular degeneration (AMD) with intravitreal injections of bevacizumab (Avastin, Genentech) in patients whose disease has not responded to therapy with the two FDA-approved and CMS-covered drug therapies-ocular photodynamic therapy with verteporfin (Visudyne, Novartis) or intravitreal pegaptanib (Macugen, OSI/Eyetech Pharmaceuticals, and Pfizer).

"This is not an endorsement of intravitreal Avastin," said H. Dunbar Hoskins, MD, AAO executive vice president. "It is a recommendation that those physicians who choose to use it should be reimbursed as they are with other off-label therapies."

Bevacizumab, a potent vascular endothelial growth factor inhibitor, was initially developed for the treatment of colorectal cancer. According to the AAO, there is increasing clinical consensus that intravitreal bevacizumab is beneficial in select patients with AMD.

The AAO will continue to monitor new information regarding the safety and efficacy of these treatments and will release new position statements when appropriate.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Mark Lobanoff, MD, on making the move to office-based surgery
Barsha Lal, PhD, discusses the way low dose atropine affects accommodative amplitude and dynamics at the 2025 ARVO meeting
(Image credit: Ophthalmology Times) NeuroOp Guru: When eye findings should prompt neuroimaging in suspected neuro-Behcet disease
At the Association for Research in Vision and Ophthalmology (ARVO) meeting, Katherine Talcott, MD, a retina specialist at Cleveland Clinic, shared her findings on EYP-1901 (EyePoint Pharmaceuticals) in the phase 2 DAVIO study.
Dr. Jogin Desai, founder of Eyestem Research, discusses his research at the Association for Research in Vision and Ophthalmology.
(Image credit: Ophthalmology Times) ASCRS 2025: Michael Rivers, MD, shares his takeaways as a panelist at the inaugural SightLine event
(Image credit: Ophthalmology Times) ASCRS 2025: Karl Stonecipher, MD, on LASIK outcomes using an aspheric excimer laser for high myopia
John Tan talks about an emergency triage framework for retinal artery occlusion at the 2025 Association for Research in Vision and Ophthalmology (ARVO) meeting.
Dr Robert Maloney at the 2025 Controversies in Modern Eye Care meeting
Wendy Lee, MD, MS, at Controversies in Modern Eye Care 2025.
© 2025 MJH Life Sciences

All rights reserved.